Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of QLM2011 in Advanced Solid Tumors
NCT06925659Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of QLM2011 in solid tumor (advanced stage) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-limiting toxicity at 21 days, Maximum tolerated dose at 1 year and 1 more. Planned start May 2025; status: not yet recruiting.
02
Drugs
QLM2011
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06925659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06925659.